AbbVie and Gedeon Richter signed an agreement to co-develop and commercialize a potential treatment for a range of neuropsychiatric diseases.
Voyager Therapeutics partnered with Novartis in a potential $1.7 billion deal. The collaboration will enable Novartis to use the gene therapy company’s capsid discovery platform to create new treatments for three undisclosed CNS targets.
Eli Lilly acquired exclusive rights to a technology from Canada-based Entos Pharmaceuticals that the Indianapolis-based company believes will boost the development of nucleic acid therapeutics that target the central and peripheral nervous systems.
Japan’s Takeda Pharmaceutical announced deals with two biotech companies, Seattle-based Immusoft and San Diego’s Poseida Therapeutics.
BioSpace takes a look at some of the top stories from day one of the Annual Biomarkers for Alzheimer’s Disease Summit held August 25-26, 2021.
The U.S. Food and Drug Administration approved Jazz Pharmaceuticals’ Xywav for idiopathic hypersomnia in adults.
BioSpace takes a look at a few of the highlights of the 24th annual meeting of the ASGCT, with researchers presenting cutting-edge work in the booming area of gene and cell therapy.
New York-based TG Therapeutics announced positive topline results from two global Phase III clinical trials, ULTIMATE I and II, of ublituximab in relapsing forms of multiple sclerosis (RMS).
Remix Therapeutics officially launched with $81 million in financing, with the funds to be used to support the development of the company’s REMaster technology platform while advancing a pipeline of RNA processing targeted therapeutics.
Biogen successfully fended off a patent challenge from generic company Mylan over the multiple sclerosis (MS) drug Tecfidera.